HeimNVAX • NASDAQ
Novavax Inc
9,32 $
13. jan., 03:05:32 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
HlutabréfSkráð hlutabréf í BandaríkinHöfuðstöðvar: Bandaríkin
Við síðustu lokun
9,61 $
Dagbil
8,95 $ - 9,55 $
Árabil
3,53 $ - 23,86 $
Markaðsvirði
1,49 ma. USD
Meðalmagn
4,13 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD)sep. 2024Breyting á/á
Tekjur
84,51 m.-54,80%
Rekstrarkostnaður
66,95 m.-37,70%
Nettótekjur
-121,30 m.7,25%
Hagnaðarhlutfall
-143,53-105,22%
Hagnaður á hvern hlut
-0,7639,68%
EBITDA
-117,12 m.-2,46%
Virkt skatthlutfall
0,84%
Heildareignir
Heildarskuldir
(USD)sep. 2024Breyting á/á
Reiðufé og skammtímafjárfestingar
909,53 m.39,69%
Heildareignir
1,71 ma.3,34%
Heildarskuldir
2,24 ma.-4,14%
Eigið fé alls
-526,44 m.
Útistandandi hlutabréf
160,18 m.
Eiginfjárgengi
-2,92
Arðsemi eigna
-18,38%
Ávöxtun eigin fjár
150,12%
Breyting á handbæru fé
(USD)sep. 2024Breyting á/á
Nettótekjur
-121,30 m.7,25%
Handbært fé frá rekstri
-144,81 m.-265,18%
Reiðufé frá fjárfestingum
31,91 m.273,52%
Reiðufé frá fjármögnun
-97,00 þ.-100,05%
Breyting á handbæru fé
-106,97 m.-172,07%
Frjálst peningaflæði
-78,48 m.-210,04%
Um
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
Framkvæmdastjóri
Stofnsett
1987
Vefsvæði
Starfsfólk
1.543
Leit
Hreinsa leit
Loka leit
Google forrit
Aðalvalmynd